Review Article
The Role of MicroRNAs in Cancer Susceptibility

Rodolfo Iuliano,1,2 Marco Flavio Michele Vismara,2,3 Vincenzo Dattilo,4 Francesco Trapasso,1,2 Francesco Baudi,1,5 and Nicola Perrotti2,4

1 Dipartimento di Medicina Sperimentale e Clinica, Università "Magna Graecia" di Catanzaro, 88100 Catanzaro, Italy
2 Unità Operativa di Genetica Medica, Università "Magna Graecia" di Catanzaro, 88100 Catanzaro, Italy
3 Dipartimento di Medicina Molecolare, Università di Roma "Sapienza", 00161 Roma, Italy
4 Dipartimento di Scienze della Salute, Università "Magna Graecia" di Catanzaro, 88100 Catanzaro, Italy
5 Centro Oncologico Fondazione T.Campanella, 88100 Catanzaro, Italy

Correspondence should be addressed to Rodolfo Iuliano; iuliano@unicz.it and Nicola Perrotti; perrotti@unicz.it

Received 19 December 2012; Accepted 14 February 2013

Academic Editor: Anna Di Gregorio

Copyright © 2013 Rodolfo Iuliano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Single nucleotide polymorphisms (SNPs) are germline variations interspersed in the human genome. These subtle changes of DNA sequence can influence the susceptibility to various pathologies including cancer. The functional meaning of SNPs is not always clear, being, the majority of them, localized in noncoding regions. The discovery of microRNAs, tiny noncoding RNAs able to bind the 3' untranslated region (UTR) of target genes and to consequently downregulate their expression, has provided a functional explanation of how some SNPs positioned in noncoding regions contribute to cancer susceptibility. In this paper we summarize the current knowledge of the effect on cancer susceptibility of SNPs included in regions related with miRNA-dependent pathways.

Hereditary cancer comes up from mutations that occur in high-penetrant predisposing tumor genes. However, a considerable part of inherited cancers arises from multiple low-penetrant predisposing gene variants that influence the behavior of cancer insurgence. Despite the established significance of such polymorphic variants in cancer predisposition, sometimes their functional role remains unknown. The discovery of a new group of genes called microRNAs (miRNAs) opened an avenue for the functional interpretation of polymorphisms involved in cancer predisposition.

1. Biogenesis of MicroRNAs

MicroRNAs are an ample class (more than one thousand) of small (19–25 nucleotides) noncoding RNAs that downregulate the expression of target genes, binding mainly their 3' untranslated region (3' UTR). Genomic regions containing microRNA genes are transcribed by RNA Polymerase II, and large RNA precursors, named pri-miRs (primary miRNAs), are generated [1]. The Pri-miRs are processed by a multiprotein complex in which the two core elements are Drosha, an enzyme with ribonuclease III activity, and Pasha (also known as DGCR8) an RNA-binding protein [2]. This processing results in the formation of a second precursor, called pre-miR, of ~70 nucleotides having a stem-loop structure with imperfect base pairings. The pre-miR is then exported by the complex Exportin5/RanGTP into the cytoplasm, where Dicer, a protein with ribonuclease III activity, cuts the RNA stem-loop structure leading to the formation of an miRNA duplex [1]. One strand of the duplex is selected, for thermodynamical reasons, to yield the mature miRNA while the other strand is degraded. Finally, the mature microRNA is loaded in a ribonuclease complex called RISC (RNA-induced silencing complex), containing the Argonaut (Ago 1–4) proteins and the GEMIN3 and GEMIN4 factors, where it pairs with the 3' UTR of target genes. The matching of miRNAs with their target genes causes the mRNA degradation or the inhibition of mRNA translation [3].

Single nucleotide polymorphisms (SNPs) related to miRNA genes, miRNA binding sites, or in genes of the miRNA processing machinery can affect the final level and function of miRNAs. This distinctive and relative new group of polymorphisms is called miRSNPs.

Target genes of microRNAs can be also oncogenes [4, 5] or tumor suppressor genes [6–8], and, hence, microRNAs are...
important players in carcinogenesis [9]. The presence of SNPs either in the genomic miRNA sequences or in the 3' UTR of cancer-related genes could influence miRNA-dependent regulation altering consequently tumor susceptibility (Figure 1) [10]. Here, we review miRSNPs studied for their relevance in the susceptibility to human cancer, indicating the associated risk expressed as odds ratio (OR) with 95% confidence interval (95% CI) (Table 1).

2. SNPs in MicroRNA Genomic Regions

SNPs can span in the entire region of the pri-miR affecting the different steps of microRNA processing or the pairing with the 3' UTR of target genes. Therefore, the expression or the sequence of the mature miRNA could be impaired, and the regulation of all gene targeted by a given miRNA could be consequently affected.

Several SNPs in microRNA regions are currently intensively investigated in different cancer types but in some cases their significance remains to be established and further studies are required to clarify their possible role in cancer predisposition.

The SNP rs2910164 is located in the pri-miRNA sequence of miR-146a and has C and G allelic forms. It was first studied by Jazdzewski et al. whom found a significant different distribution of genotypes, in patients with papillary thyroid carcinomas compared with normal subjects, being the GC genotype associated with an increased risk of papillary thyroid carcinoma (OR = 1.62; 95% CI: 1.3–2.0; P = 0.0000007) [11]. Furthermore, the authors demonstrated that in heterozygotes the expression of mature miR-146a is reduced. Wang et al. showed that the C allele of SNP rs2910164 is associated with significantly decreased risk of bladder cancer (OR = 0.80; 95% CI: 0.71–0.90), and GC/CC genotypes confer a significantly reduced risk of recurrence, compared with the GG genotype. The same authors demonstrated by functional studies that the miR-146a rs2910164 C allele inhibits proliferation in bladder cancer cells [12]. In a case-control study, Lung et al. showed that CC genotype of rs2910164 was associated with an increased risk of nasopharyngeal carcinoma (NPC) (GC + GG versus CC, OR = 0.49; 95% CI: 0.35–0.69). The authors also demonstrated that passenger strand miR-146a* C in NPC is significantly increased in CC genotype, resulting in the regulation of a set of target genes [13]. The allelic variants of rs2910164 were evaluated in familial breast and ovarian cancers in BRCA1/BRCA2-negative patients in a study which suggested that the polymorphism may impact on the age of cancer onset. In fact, subjects with GC or CC genotypes developed tumors at younger age compared with individuals carrying the GG genotype [14]. However, a large study of breast cancer cases negative for disease-causing mutations or unclassified variants in BRCA1 and BRCA2 showed no associations between rs2910164 genotype and breast cancer susceptibility [15]. Another study showed also lack of association of the rs2910164 SNP with breast cancer risk in a series of BRCA1 and BRCA2 mutation carriers [16]. In a meth-analysis study, a stratified analysis by ethnicity showed that the rs2910164 polymorphism is associated with increased breast cancer risk among Europeans in a recessive model (CC versus GC + GG: OR = 1.31; 95% CI: 1.05–1.65) [17]. In another meta-analysis was shown that SNP rs2910164 is not associated with the risk of hepatocellular carcinoma [18]. Thus, the C allele of rs2910164 seems to be associated with cancer risk in a cancer type specific manner, but further studies are required to better clarify this matter. In addition, other functional studies should define the role of the polymorphism in the expression of miR-146a.

The SNP rs11614913 is located in the pre-miRNA region of miR-196a2 and has two allelic forms, T and C. Hu et al. found that in nonsmall cell lung cancer patients who were homozygous CC at SNP rs11614913, risk of death significantly increased (hazard ratio HR = 1.76; 95% CI: 1.34–2.32). The genotype rs11614913 CC was associated with a significant increase in mature hsa-mir-196a expression without changes in levels of the precursor, suggesting an enhanced processing of the pre-miRNA [19, 20]. The miR-196a2 CC genotype was also associated with reduced survival in patients with pharyngeal tumors [21] increased colorectal cancer risk [22] and increased breast cancer risk [23] compared with the TT/CT genotype. However, in breast cancer, Catucci et al. found no significant increased risk in rs11614913 CC homozygous patients [15]. A meta-analysis of 15 studies showed that individuals with the TC/CC genotypes are associated with higher cancer risk than those with the TT genotype (OR = 1.18; 95% CI: 1.03–1.34; P < 0.0001) supporting the hypothesis that hsa-miR-196a2 rs11614913 polymorphism may contribute to cancer susceptibility [24].

The SNP rs6505162 is an A/C polymorphism located in the pre-miRNA region of miR-423. Ye et al. systematically evaluated the effects of 41 genetic variants in 26 miRNA-related genes on esophageal cancer risk. The most relevant finding was the association of rs6505162 SNP with reduced esophageal cancer risk, following an additive model (OR = 0.64; 95% CI: 0.51–0.80, P < 0.0001), being the C allele less represented in cases than in controls [25]. For the same polymorphism, a study that was performed on Caucasian Australian patients showed that CC genotype confers a reduced risk of breast cancer development (OR = 0.50; 95% CI: 0.27–0.92) [26]. In a sample of Chinese patients with surgically resected colorectal adenocarcinoma, homozygous CC genotypes of SNP rs6505162 were significantly associated with both the overall survival (HR = 2.12; 95% CI: 1.34–3.34, P = 0.001) and the recurrence-free survival (HR = 1.59; 95% CI: 1.08–2.36) [27].

The SNP rs37464444, having the two alleles A and G, is located in the pre-miR region of miR-499. In a case-control study on a Chinese population, the variant G was associated with a significant increased risks of breast cancer (OR = 1.25; 95% CI: 1.02–1.51) in a dominant genetic model [23]. This association was not confirmed by the study of Catucci et al. performed on a Caucasian population [15]. In a meta-analysis study the rs37464444 polymorphism was significantly associated with breast cancer risk in Asian population, being the G allele responsible for the increased risk (OR = 1.10; 95% CI: 1.01–1.20) [28]. Moreover, the rs37464444 polymorphism was associated with a significant increased risk (OR = 1.98; 95% CI: 1.36–2.98; P = 0.0004) of cervical squamous cell carcinoma, following an overdominant model [29].
SNP rs4919510 is located in pre-miRNA region of miR-608 and has C and G alleles. The relevance of this polymorphism has been studied in patients with colorectal cancer (CRC). In CRC patients receiving first-line fluoropyrimidine-based chemotherapy several SNPs located in miRNA regions were genotyped, the rs4919510 resulted associated with increased risk for both recurrence and death (HR = 2.72; 95% CI: 1.38–5.33 and HR = 3.53; 95% CI: 1.42–8.73) [30]. These findings were confirmed by an independent study, in which rs4919510 was associated with altered recurrence-free survival only in patients receiving chemotherapy but not in those without chemotherapy [27]. In another study, there was no significant association found between rs4919510 and colorectal cancer risk, but the GG genotype was associated with an increased risk of death in Caucasians and with a reduced risk of death in African Americans [31]. Recently,
Table 1: List of miRSNPs evaluated in cancer susceptibility studies.

<table>
<thead>
<tr>
<th>SNP category</th>
<th>Cancer type</th>
<th>SNP</th>
<th>Gene</th>
<th>OR (95% CI)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miRNA sequence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Any cancer</td>
<td>rs11614913</td>
<td>miR-196a2</td>
<td>1.18 (1.03–1.34)</td>
<td>[24]</td>
</tr>
<tr>
<td></td>
<td>Bladder cancer</td>
<td>rs2910164</td>
<td>miR-146-a</td>
<td>0.80 (0.71–0.90)</td>
<td>[12]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs895819</td>
<td>miR-27a</td>
<td>0.88 (0.78–0.99)</td>
<td>[33]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs2910164</td>
<td>miR-146-a</td>
<td>1.31 (1.05–1.65)</td>
<td>[17]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs11614913</td>
<td>miR-196a2</td>
<td>1.23 (1.02–1.48)</td>
<td>[23]</td>
</tr>
<tr>
<td></td>
<td>Breast cancer</td>
<td>rs6505162</td>
<td>miR-423</td>
<td>0.50 (0.27–0.92)</td>
<td>[26]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs3746444</td>
<td>miR-499</td>
<td>1.25 (1.02–1.51)</td>
<td>[23]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs3746444</td>
<td>miR-499</td>
<td>1.10 (1.01–1.20)</td>
<td>[28]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs4919510</td>
<td>miR-608</td>
<td>1.62 (1.23–2.15)</td>
<td>[32]</td>
</tr>
<tr>
<td></td>
<td>Cervical cancer</td>
<td>rs3746444</td>
<td>miR-499</td>
<td>1.98 (1.36–2.89)</td>
<td>[29]</td>
</tr>
<tr>
<td></td>
<td>Colorectal carcinoma</td>
<td>rs213210</td>
<td>miR-219-1</td>
<td>3.22 (1.70–6.10)</td>
<td>[30]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs6505162</td>
<td>miR-423</td>
<td>2.12 (1.34–3.34)</td>
<td>[27]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs4919510</td>
<td>miR-608</td>
<td>2.72 (1.38–5.33)</td>
<td>[30]</td>
</tr>
<tr>
<td></td>
<td>Esophageal cancer</td>
<td>rs213210</td>
<td>miR-219-1</td>
<td>1.75 (1.10–2.80)</td>
<td>[25]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs6505162</td>
<td>miR-423</td>
<td>0.64 (0.51–0.80)</td>
<td>[25]</td>
</tr>
<tr>
<td></td>
<td>Gastric cancer</td>
<td>rs895819</td>
<td>miR-27a</td>
<td>1.48 (1.06–2.05)</td>
<td>[37]</td>
</tr>
<tr>
<td></td>
<td>Nasopharyngeal carcinoma</td>
<td>rs2910164</td>
<td>miR-146-a</td>
<td>0.49 (0.35–0.69)</td>
<td>[13]</td>
</tr>
<tr>
<td></td>
<td>Non-small cell lung cancer</td>
<td>rs11614913</td>
<td>miR-196a2</td>
<td>1.76 (1.34–2.32)</td>
<td>[19]</td>
</tr>
<tr>
<td></td>
<td>Papillary thyroid carcinoma</td>
<td>rs2910164</td>
<td>miR-146-a</td>
<td>1.62 (1.3–2.0)</td>
<td>[11]</td>
</tr>
<tr>
<td></td>
<td>Renal carcinoma</td>
<td>rs895819</td>
<td>miR-27a</td>
<td>0.71 (0.56–0.90)</td>
<td>[36]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Binding site</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bladder cancer</td>
<td>rs61764370</td>
<td>Kras</td>
<td>1.47 (1.05–2.06)</td>
<td>[39]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs7963551</td>
<td>Rad52</td>
<td>0.84 (0.75–0.95)</td>
<td>[50]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs1044129</td>
<td>Ryr3</td>
<td>1.26 (1.03–1.54)</td>
<td>[59]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs334248</td>
<td>Tgfbr1</td>
<td>2.2 (1.29–4.07)</td>
<td>[47]</td>
</tr>
<tr>
<td></td>
<td>Colorectal carcinoma</td>
<td>rs7281995</td>
<td>Cdx8</td>
<td>2.93 (1.29–6.67)</td>
<td>[58]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs1051690</td>
<td>Insr</td>
<td>2.06 (1.19–3.56)</td>
<td>[58]</td>
</tr>
<tr>
<td></td>
<td>Non-small cell lung cancer</td>
<td>rs61764370</td>
<td>Kras</td>
<td>1.36 (1.07–1.73)</td>
<td>[38]</td>
</tr>
<tr>
<td></td>
<td>Ovarian cancer</td>
<td>rs61764370</td>
<td>Kras</td>
<td>1.67 (1.09–2.57)</td>
<td>[43]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs4245739</td>
<td>Mdm4</td>
<td>5.5 (1.5–20.5)</td>
<td>[61]</td>
</tr>
<tr>
<td></td>
<td>Small-cell lung cancer</td>
<td>rs3134615</td>
<td>Mycl1</td>
<td>2.08 (1.39–3.21)</td>
<td>[49]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs16917496</td>
<td>Set8</td>
<td>0.45 (0.22–0.94)</td>
<td>[54]</td>
</tr>
<tr>
<td></td>
<td>Squamous cell carcinoma of the head and neck</td>
<td>rs1049253</td>
<td>Casp3</td>
<td>1.29 (1.07–1.56)</td>
<td>[56]</td>
</tr>
<tr>
<td></td>
<td>Biogenesis pathway</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Breast cancer</td>
<td>rs11786030</td>
<td>AGO2</td>
<td>2.62 (1.41–4.88)</td>
<td>[66]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs2927779</td>
<td>AGO2</td>
<td>2.94 (1.52–5.69)</td>
<td>[66]</td>
</tr>
<tr>
<td></td>
<td>Head and neck cancer</td>
<td>rs1057035</td>
<td>Dicer</td>
<td>0.65 (0.46–0.92)</td>
<td>[69]</td>
</tr>
<tr>
<td></td>
<td>Non-small cell lung cancer</td>
<td>rs11077</td>
<td>Xpo5</td>
<td>1.77 (1.07–2.91)</td>
<td>[68]</td>
</tr>
<tr>
<td></td>
<td>Prostate cancer</td>
<td>rs2740348</td>
<td>Gemin4</td>
<td>0.64 (0.42–0.99)</td>
<td>[67]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs7813</td>
<td>Gemin4</td>
<td>2.53 (1.07–6.28)</td>
<td>[67]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs3744741</td>
<td>Gemin4</td>
<td>0.69 (0.50–0.96)</td>
<td>[67]</td>
</tr>
<tr>
<td></td>
<td>Renal carcinoma</td>
<td>rs2740348</td>
<td>Gemin4</td>
<td>0.67 (0.47–0.96)</td>
<td>[64]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs7813</td>
<td>Gemin4</td>
<td>0.68 (0.47–0.98)</td>
<td>[64]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs910925</td>
<td>Gemin4</td>
<td>1.74 (1.15–2.62)</td>
<td>[65]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs3744741</td>
<td>Gemin4</td>
<td>0.39 (0.19–0.77)</td>
<td>[65]</td>
</tr>
</tbody>
</table>
rs4919510 was studied in breast cancer patients, and the G-allele was specifically associated with an increased risk of HER2-positive subtype (OR = 1.62; 95% CI: 1.23–2.15) [32].

The SNP rs895819 is located in the pre-miRNA-27a and has A and G alleles. The role of this SNP was first investigated in a German familial breast cancer study cohort, in which SNPs related to other microRNAs were also analyzed. The G allele of SNP rs895819 resulted significantly less frequent in cases than in controls, indicating a lower familial breast cancer risk for patients carrying this variant (OR = 0.88; 95% CI: 0.78–0.99) [33]. The same conclusion was not confirmed in an Italian breast cancer cohort with similar characteristics [34]. The discordance between these two studies was further investigated, and it is probably due to technical aspects concerning the genotyping method used [35]. In a case-control study on renal carcinoma, individuals carrying AG/GG genotypes of SNP rs895819 had a statistically significant lower susceptibility in the development of renal cancer (OR = 0.71; 95% CI: 0.56–0.90) [36].

rs895819 was studied in breast cancer patients, and the G-allele was specifically associated with an increased risk of HER2-positive subtype (OR = 1.62; 95% CI: 1.23–2.15) [32]. These authors showed that the less common G variant of rs61764370 disrupts significantly the binding of microRNA let-7 to the 3′ UTR of KRAS, increasing KRAS expression. In addition, in that study was found that subjects (smoking < 40 pack/year) with the GG + GT genotypes have an increased risk (OR = 1.36; 95% CI: 1.07–1.73; P = 0.01) of nonsmall lung cancer. After this first study, G variant of rs61764370 was found associated with higher risk in breast cancer [39], colorectal cancer [40], melanoma [41], oral cancers [42], and ovarian cancer [43]. Conversely, other authors did not find significant association of rs61764370 with cancer risk in colorectal cancer [44], nonsmall lung cancer [45], and ovarian cancer [46]. Thus, the relevance of rs61764370 in cancer predisposition is still debated and deserves further investigations.

The SNP rs334348 is located in the 3′ UTR of TGFBR1 gene and has A and G variants. Nicoloso et al. found that subjects with AG genotype has higher susceptibility to familiar breast cancer (OR = 2.2; 95% CI: 1.29–4.07; P = 0.005) [47]. Functionally, it was shown that the G allele of rs334348 is targeted with higher efficiency by miR-628-5p than the A allele. This was demonstrated by luciferase assay using the cloned alternative forms of TGFBR1 3′ UTR and by western blot using breast cancer cell lines with different genotypes. Notably, the expression of TGFBR1 influences significantly the colorectal cancer risk [48].

The SNP rs3134615 is in the 3′ UTR of MYCLI, within a miR-1827 binding site, and has G and T alleles. In a case-control study, Xiong et al. showed that subjects with TG and TT genotypes have an increased risk (OR = 2.08; 95% CI: 1.39–3.21; P = 0.0004) for the development of small-cell lung cancer [49]. Moreover, the same authors demonstrated that the T allele significantly impairs the interaction of miR-1827 with the 3′ UTR of MYCLI, reducing miR-1827 dependent inhibition of MYCLI expression.

The SNP rs7963551 is located in the 3′ UTR of RAD52 and has C and A variants. RAD52 encodes a protein involved in homologous recombination repair. In a study performed to evaluate the relevance of rs7963551 on breast cancer susceptibility, the C allele was associated with reduced cancer risk (OR = 0.84; 95% CI: 0.75–0.95). Moreover, a reduced inhibition of RAD52 expression of C allele, probably due to a weakened binding capacity of hsa-let-7 to 3′-UTR of RAD52, was demonstrated by luciferase activity assay in MCF-7 cell line [50].

The rs61917496 is a C/T variation located in the 3′ UTR of SET8 within the miR-502 binding site, having the C allele a perfect match in the seed region of miR-502. The expression of SET8 in breast tumor tissues of patients with a CC genotype is significantly lower than in patients with TT genotype, and, importantly, the age of breast cancer onset depends on the number of C alleles, being significantly lower in C allele carriers (P = 0.022) [51]. This is in agreement with the role played by SET8, a methyltransferase that acts on p53 increasing its proapoptotic potential [52]. It was found that the SET8 CC genotype confers also longer survival to
patients with hepatocellular carcinoma [53] and with small-cell lung cancer [54], and it is associated with a decreased risk of epithelial ovarian cancer [55].

The rs1049253 is a C/T variation located in the 3' UTR of CASP3 gene within the binding site of miR-885-5p. CASP3 belongs to the caspase family genes encoding key effector enzymes involved in cell apoptosis. Downregulation of caspases affects programmed cell death allowing tumor cell proliferation. A study on 7 SNPs located in the 3' UTR of caspase genes was performed to assess their possible association with squamous cell carcinoma of the head and neck. The genotypes CC/CT rs1049253 resulted associated with significantly increased cancer risk (OR = 1.29; 95% CI: 1.07–1.56), but no associations were found for the other 6 SNPs. Moreover, the rs1049253 CC genotype was associated with reduced levels of CASP3 mRNA compared with the TT genotype, and C allele resulted in stronger down-regulation than T allele of the CASP3 expression determined with miR-885-5p mimic transfection and luciferase assay [56].

In a study of Landi et al. [57], SNPs located in the miRNA binding sites of 3' UTR of genes relevant in the pathogenesis of colorectal cancer (CRC) were computationally tested for their ability to affect the binding of the miRNA with its target. Eight polymorphisms were further studied by case-control studies and two of them, rs17281995 and rs1051690, located in the CD86 and INSR genes respectively, resulted significantly associated with CRC risk. In a subsequent paper [58], the same authors extended the study of rs17281995 and rs1051690 polymorphisms in CRC risk, analyzing an additional population (OR = 2.93; 95% CI: 1.29–6.67, for rs17281995 and OR = 2.06; 95% CI: 1.19–3.56, for rs1051690, in the pooled samples, following a codominant model).

The SNP rs1044129 is a G/A variation located in the 3' UTR of RYR3 gene in the miR-367 binding site. RYR3 encodes a protein that forms a calcium channel which is relevant for cell growth and migration of breast cancer cells. In a case-control study, AA genotype carriers showed a significantly higher breast cancer risk (OR = 1.26, 95% CI: 1.07–1.56), but no associations were found for the other 6 SNPs. Moreover, the rs1044129 CC genotype was associated with a significantly reduced risk, with odds ratios of 0.67 (95% CI: 0.47–0.96) and 0.68 (95% CI = 0.47–0.98), respectively. Haplotype analysis showed that a common haplotype of GEMIN4 was associated with a significant reduction in the risk of renal cell carcinoma (OR = 0.66; 95% CI: 0.45–0.97).

The same research group, in a successive study [65], took a polygenic approach to evaluate the effects of 41 potentially functional SNPs in miRNAs-related genes on survival and recurrence among renal cell carcinoma (RCC) patients. In single-SNP analysis, seven SNPs were identified significantly associated with RCC survival and five SNPs with recurrence. The most significant associations were SNPs in GEMIN4 with the variant alleles of both rs7813 and rs910925 associated with a significant reduction in the risk of renal cell carcinoma (OR = 0.66; 95% CI: 0.45–0.97). Haplotype analysis showed that a common haplotype of DICER and DROSHA were also associated with altered patient survival and recurrence.

To test the hypothesis that adverse alleles in miRNA-related genes may influence the risk for esophageal cancer, the associations between esophageal cancer risk and 41 potentially functional SNPs in 26 miRNA-related genes were assessed, in a case-control study [25]. A common haplotype of the GEMIN4 gene was associated with a significantly reduced risk of esophageal cancer (OR = 0.65; 95% CI: 0.42–0.99).

In a recent study [66], the authors used genotype data available from a previous case-control study to investigate
association between common genetic variations in miRNA biogenesis pathway genes and breast cancer survival. They investigated the possible associations between 41 SNPs and both disease-free survival (DFS) and overall survival (OS) among 488 breast cancer patients. Two SNPs in AGO2 (rs11786030 and rs2292779) and DICER1 rs1057035 were associated with both DFS and OS. Two SNPs in HIWI (rs4759659 and rs1060845), and DGCGR8 rs9606250 were associated with DFS, while DROSHA rs874332 and GEMIN4 rs4968104 were associated with OS only. The most significant associations were observed in variant allele of AGO2 rs11786030 with 2.62-fold increased risk of disease progression (95% CI: 1.41–4.88) and in minor allele homozygote of AGO2 rs2292779 with 2.94-fold increased risk of death (95% CI: 1.52–5.69).

A recent study was performed in order to evaluate the role of miR-SNPs of GEMIN4 in prostate cancer [67]. The high-resolution melting method was used to genotype seven polymorphisms (rs7813, rs4968104, rs3744741, rs2740348, rs1062923, rs910925, and rs910924) in the GEMIN4 gene. Patients carrying the variant heterozygote GC genotype in the rs2740348 were at a 36% decreased risk of prostate cancer (OR = 0.64; 95% CI: 0.42–0.99). In addition, subjects carrying the homozygote TT genotype in the rs7813 had a significantly increased risk of prostate cancer (OR = 2.53; 95% CI = 1.07–6.28). Two common haplotypes were found to be associated with decreased risk of prostate cancer. In the subgroup analysis, higher risk of more severity of prostate cancer (clinical stage III and IV) was observed in individuals with the rs7813 TT genotype (OR = 2.64; 95% CI: 1.02–7.64), while lower risk of more severity of prostate cancer was observed in individuals with the rs3744741 T allele (OR = 0.69; 95% CI: 0.50–0.96).

In a study on a sample of nonsmall-cell lung cancer patients [68], three miR-SNPs in microRNA-processing machinery components were examined, and the time to recurrence (TTR) according to miR-SNP genotypes was evaluated. Significant differences in TTR were found for XPO5 rs11077 (median TTR: 24.7 months for the AA genotype and in minor allele homozygote of XPO5 rs1077 AA genotype (OR = 0.77; 95% CI: 1.07–2.91) emerged as independent variable influencing TTR.

In a recent case-control study on head and neck cancer (HNC) [69], three SNPs at miRNA binding sites of miRNA processing genes were genotyped (rs1057035 in 3'UTR of DICER, rs3803012 in 3'UTR of RAN, and rs10773771 in 3'UTR of HIWI). Although none of the SNPs was significantly associated with overall risk of HNC, rs1057035 in 3'UTR of DICER was associated with a significantly decreased risk of oral cancer (TC/CC versus TT, OR = 0.65; 95% CI: 0.46–0.92). Furthermore, luciferase activity assay showed that rs1057035 variant C allele led to significantly lower expression levels of DICER as compared to the T allele, which may be due to the higher inhibition of hsa-miR-574-3p on DICER mRNA. These findings indicated that rs1057035 located at 3'UTR of DICER may contribute to the risk of oral cancer by affecting the binding of miRNAs to DICER. Large-scale and well-designed studies are warranted to validate these findings.

A sample of patients with chemosensitive multiple myeloma intensified with autologous stem cell transplantation was studied in a longitudinal study [70]. The SNP of miRNA biogenesis pathway evaluated was the rs11077 of XPO5. Overall survival was significantly longer in patients with C/C or A/C variant in XPO5 rs11077 (P = 0.012). A significant longer progression-free survival for this SNP (P = 0.013) was also found.

5. Conclusions
The study of polymorphisms, affecting miRNA-dependent pathways and involved in cancer susceptibility, is rapidly growing, and in the near future probably other SNPs will be investigated, and the SNPs mentioned in this paper will be further evaluated. The acquisition of new data in different populations has a paramount importance to establish the real contribution of each polymorphism to the cancer risk in this promising area.

Acknowledgment
This study was supported by the Italian Ministry of Education, University and Research, Grant no. 2010JCWWKM_002.

References


